
Yellela Krishaiah

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4715163/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Asymmetric flow field flow fractionation for the characterization of globule size distribution in complex formulations: A cyclosporine ophthalmic emulsion case. International Journal of Pharmaceutics, 2018, 538, 215-222.	5.2	20
2	Development and validation of a UPLC–MS method for the determination of galantamine in guinea pig plasma and its application to a preâ€clinical bioavailability study of novel galantamine formulations. Biomedical Chromatography, 2018, 32, e4275.	1.7	4
3	Quality by Design approach for studying the impact of formulation and process variables on product quality of oral disintegrating films. International Journal of Pharmaceutics, 2017, 527, 151-160.	5.2	35
4	Hyperspectral imaging using near infrared spectroscopy to monitor coat thickness uniformity in the manufacture of a transdermal drug delivery system. International Journal of Pharmaceutics, 2017, 523, 281-290.	5.2	11
5	In Vitro Drug Transfer Due to Drug Retention in Human Epidermis Pretreated with Application of Marketed Estradiol Transdermal Systems. AAPS PharmSciTech, 2017, 18, 2131-2140.	3.3	2
6	Enantioselective penetration enhancing effect of carvone on the <i>in vitro</i> transdermal permeation of nicorandil. Pharmaceutical Development and Technology, 2012, 17, 574-582.	2.4	5
7	Analysis of vitamin E in commercial cosmetic preparations by HPLC. Journal of Cosmetic Science, 2010, 61, 353-65.	0.1	9
8	Effect of PEG6000 on the In Vitro and In Vivo Transdermal Permeation of Ondansetron Hydrochloride from EVA1802 Membranes. Pharmaceutical Development and Technology, 2009, 14, 53-64.	2.4	9
9	Penetration-Enhancing Effect of Ethanolic Solution of Menthol on Transdermal Permeation of Ondansetron Hydrochloride Across Rat Epidermis. Drug Delivery, 2008, 15, 227-234.	5.7	21
10	Studies on Optimizing In Vitro Transdermal Permeation of Ondansetron Hydrochloride Using Nerodilol, Carvone, and Limonene as Penetration Enhancers. Pharmaceutical Development and Technology, 2008, 13, 177-185.	2.4	12
11	Controlled In Vivo Release of Nicorandil from a Carvone-Based Transdermal Therapeutic System in Human Volunteers. Drug Delivery, 2006, 13, 69-77.	5.7	7
12	Pharmacokinetic evaluation and studies on the clinical efficacy of guar gumbased oral drug delivery systems of albendazole and albendazole-β-cyclodextrin for colon-targeting in human volunteers. Drug Development Research, 2006, 67, 154-165.	2.9	12
13	In vitro and in vivo evaluation of guar gum matrix tablets for oral controlled release of water-soluble diltiazem hydrochloride. AAPS PharmSciTech, 2005, 6, E14-E21.	3.3	54
14	Bioavailability of nerodilol-based transdermal therapeutic system of nicorandil in human volunteers. Journal of Controlled Release, 2005, 106, 111-122.	9.9	16
15	Development of colon-targeted albendazole-β-cyclodextrin-complex drug delivery systems. Drug Development Research, 2005, 65, 76-83.	2.9	17
16	In vivo Evaluation of Limonene-Based Transdermal Therapeutic System of Nicorandil in Healthy Human Volunteers. Skin Pharmacology and Physiology, 2005, 18, 263-272.	2.5	6
17	Penetrationâ€Enhancing Effect of Ethanol–Water Solvent System and Ethanolic Solution of Carvone on Transdermal Permeability of Nimodipine from HPMC Gel Across Rat Abdominal Skin. Pharmaceutical Development and Technology, 2004, 9, 63-74.	2.4	24
18	Formulation and Evaluation of Limonene-Based Membrane-Moderated Transdermal Therapeutic System of Nimodipine. Drug Delivery, 2004, 11, 1-9.	5.7	11

Yellela Krishaiah

#	Article	IF	CITATIONS
19	Formulation of an HPMC Gel Drug Reservoir System with Ethanol-Water as a Solvent System and Limonene as a Penetration Enhancer for Enhancing in vitro Transdermal Delivery of Nicorandil. Skin Pharmacology and Physiology, 2004, 17, 310-320.	2.5	22
20	Pharmacokinetic evaluation of guar gum-based three-layer matrix tablets for oral controlled delivery of highly soluble metoprolol tartrate as a model drug. European Journal of Pharmaceutics and Biopharmaceutics, 2004, 58, 697-703.	4.3	42
21	Pharmacokinetic evaluation of guar gum-based colon-targeted oral drug delivery systems of metronidazole in healthy volunteers. European Journal of Drug Metabolism and Pharmacokinetics, 2003, 28, 287-294.	1.6	10
22	In vivo pharmacokinetics in human volunteers: oral administered guar gum-based colon-targeted 5-fluorouracil tablets. European Journal of Pharmaceutical Sciences, 2003, 19, 355-362.	4.0	86
23	Pharmacokinetic evaluation of guar gum-based colon-targeted drug delivery systems of mebendazole in healthy volunteers. Journal of Controlled Release, 2003, 88, 95-103.	9.9	58
24	Influence of menthol and pressure-sensitive adhesives on the in vivo performance of membrane-moderated transdermal therapeutic system of nicardipine hydrochloride in human volunteers. European Journal of Pharmaceutics and Biopharmaceutics, 2003, 55, 329-337.	4.3	24
25	Formulation and In Vivo Evaluation of Membrane-Moderated Transdermal Therapeutic Systems of Nicardipine Hydrochloride using Carvone as a Penetration Enhancer. Drug Delivery, 2003, 10, 101-109.	5.7	13
26	In Vivo Evaluation of Guar Gum-based Colon-targeted Drug Delivery Systems of Ornidazole in Healthy Human Volunteers. Journal of Drug Targeting, 2003, 11, 109-115.	4.4	21
27	Studies on the Development of Colon Targeted Oral Drug Delivery Systems for Ornidazole in the Treatment of Amoebiasis. Drug Delivery, 2003, 10, 111-117.	5.7	20
28	Penetration Enhancing Effect of Menthol on the Percutaneous Flux of Nicardipine Hydrochloride Through Excised Rat Epidermis from Hydroxypropyl Cellulose Gels. Pharmaceutical Development and Technology, 2002, 7, 305-315.	2.4	47
29	Design and In Vitro Evaluation of Oral Colon Targeted Drug Delivery Systems for Tinidazole. Journal of Drug Targeting, 2002, 10, 579-584.	4.4	16
30	The Determination of Mosapride Citrate in Bulk Drug Samples and Pharmaceutical Dosage Forms Using HPLC Analytical Sciences, 2002, 18, 1269-1271.	1.6	15
31	Studies on the Development of Colon-targeted Delivery Systems for Celecoxib in the Prevention of Colorectal Cancer. Journal of Drug Targeting, 2002, 10, 247-254.	4.4	44
32	Three-layer guar gum matrix tablet formulations for oral controlled delivery of highly soluble trimetazidine dihydrochloride. Journal of Controlled Release, 2002, 81, 45-56.	9.9	87
33	Bioavailability studies on guar gum-based three-layer matrix tablets of trimetazidine dihydrochloride in human volunteers. Journal of Controlled Release, 2002, 83, 231-239.	9.9	25
34	In vitro drug release studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil. European Journal of Pharmaceutical Sciences, 2002, 16, 185-192.	4.0	157
35	In vivo evaluation of guargum-based colon-targeted oral drug delivery systems of celecoxib in human volunteers. European Journal of Drug Metabolism and Pharmacokinetics, 2002, 27, 273-280.	1.6	15
36	Studies on the development of oral colon targeted drug delivery systems for metronidazole in the treatment of amoebiasis. International Journal of Pharmaceutics, 2002, 236, 43-55.	5.2	100

Yellela Krishaiah

#	Article	IF	CITATIONS
37	A three-layer guar gum matrix tablet for oral controlled delivery of highly soluble metoprolol tartrate. International Journal of Pharmaceutics, 2002, 241, 353-366.	5.2	58
38	Influence of limonene on the bioavailability of nicardipine hydrochloride from membrane-moderated transdermal therapeutic systems in human volunteers. International Journal of Pharmaceutics, 2002, 247, 91-102.	5.2	44
39	Development of colon targeted drug delivery systems for mebendazole. Journal of Controlled Release, 2001, 77, 87-95.	9.9	77
40	In vitro evaluation of guar gum as a carrier for colon-specific drug delivery. Journal of Controlled Release, 1998, 51, 281-287.	9.9	174
41	Gamma scintigraphic studies on guar gum matrix tablets for colonic drug delivery in healthy human volunteers. Journal of Controlled Release, 1998, 55, 245-252.	9.9	135
42	Evaluation of guar gum as a compression coat for drug targeting to colon. International Journal of Pharmaceutics, 1998, 171, 137-146.	5.2	110
43	Interaction between tolbutamide and ketoconazole in healthy subjects British Journal of Clinical Pharmacology, 1994, 37, 205-207.	2.4	31